Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more
Lineage Cell Therapeutics Inc (LCTX) - Total Liabilities
Latest total liabilities as of September 2025: $68.84 Million USD
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has total liabilities worth $68.84 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lineage Cell Therapeutics Inc - Total Liabilities Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lineage Cell Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quadient SA
PA:QDT
|
France | €1.41 Billion |
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
China | CN¥562.84 Million |
|
Guangdong Vanward New Electric Co Ltd
SHE:002543
|
China | CN¥3.36 Billion |
|
Zbom Cabinets Co Ltd
SHG:603801
|
China | CN¥2.99 Billion |
|
Zhejiang Yilida Ventilator Co Ltd
SHE:002686
|
China | CN¥1.28 Billion |
|
Blue Water Acquisition Corp. III Unit.
NASDAQ:BLUWU
|
USA | $9.15 Million |
Liability Composition Analysis (1991–2024)
This chart breaks down Lineage Cell Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lineage Cell Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual total liabilities of Lineage Cell Therapeutics Inc from 1991 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.21 Million | -7.15% |
| 2023-12-31 | $39.00 Million | -24.61% |
| 2022-12-31 | $51.73 Million | -38.16% |
| 2021-12-31 | $83.65 Million | +552.37% |
| 2020-12-31 | $12.82 Million | -9.90% |
| 2019-12-31 | $14.23 Million | +51.17% |
| 2018-12-31 | $9.41 Million | +4.86% |
| 2017-12-31 | $8.98 Million | -25.58% |
| 2016-12-31 | $12.06 Million | -33.76% |
| 2015-12-31 | $18.21 Million | +49.55% |
| 2014-12-31 | $12.18 Million | -21.27% |
| 2013-12-31 | $15.47 Million | +183.59% |
| 2012-12-31 | $5.45 Million | +24.77% |
| 2011-12-31 | $4.37 Million | +13.63% |
| 2010-12-31 | $3.85 Million | +61.23% |
| 2009-12-31 | $2.39 Million | -55.67% |
| 2008-12-31 | $5.38 Million | +67.07% |
| 2007-12-31 | $3.22 Million | +28.05% |
| 2006-12-31 | $2.52 Million | +16.72% |
| 2005-12-31 | $2.16 Million | +83.15% |
| 2004-12-31 | $1.18 Million | -66.40% |
| 2003-12-31 | $3.50 Million | +31.30% |
| 2002-12-31 | $2.67 Million | +30.72% |
| 2001-12-31 | $2.04 Million | +467.19% |
| 2000-12-31 | $359.75K | -39.59% |
| 1999-12-31 | $595.51K | +48.88% |
| 1998-12-31 | $400.00K | -77.78% |
| 1997-12-31 | $1.80 Million | +800.00% |
| 1996-12-31 | $200.00K | 0.00% |
| 1995-12-31 | $200.00K | -50.00% |
| 1994-12-31 | $400.00K | +300.00% |
| 1993-12-31 | $100.00K | 0.00% |
| 1992-12-31 | $100.00K | -50.00% |
| 1991-12-31 | $200.00K | -- |